CAIRE acquires respiratory device maker
By HME News Staff
Updated Fri June 5, 2020
BALL GROUND, Ga. - CAIRE has acquired Spirosure, a California-based company that recently launched its first product to market, the Fenom Pro, a device that measures FeNO, a key indicator of allergic inflammation in asthmatic patients. “FeNo is quickly becoming recognized by the clinical community as an important diagnostic and management tool for clinicians who treat asthma patients,” said Earl Lawson, CAIRE president and CEO. “The acquisition of Spirosure further diversifies our portfolio and provides access to the $5 billion respiratory diagnostic sector.” Spirosure will operate as a division of CAIRE called CAIRE Diagnostics.
Comments